{"id":"W2623521568","doi":"10.1136/annrheumdis-2016-210459","title":"Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":186,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Infection and Immunity","funders":"Amgen","keywords":"Adalimumab; Medicine; Rheumatoid arthritis; Clinical endpoint; Internal medicine; Adverse effect; Bioequivalence; Pharmacokinetics; Gastroenterology; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003838193,0.001063482,0.00268795,0.0004058499,0.0004731629,0.0009759343,0.0007678472,0.001682005,0.006615631],"category_scores_gemma":[0.004348096,0.0006564369,0.001996742,0.0003822706,0.001312483,0.001054622,0.0004417394,0.001941486,0.000901035],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006692003,"about_ca_system_score_gemma":0.0009970745,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003963694,"about_ca_topic_score_gemma":0.0006116407,"domain_scores_codex":[0.9979735,0.001316858,0.0002003628,0.0001969192,0.0001941777,0.0001181809],"domain_scores_gemma":[0.9972602,0.001039054,0.0006920588,0.0001968534,0.0002268155,0.0005850494],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9739822,0.009211513,0.0007294298,0.0004606923,0.0005566762,0.00002969741,0.00007029327,0.0001446222,0.003667991,0.00005270348,0.0002293301,0.01086492],"study_design_scores_gemma":[0.7780782,0.2161423,0.003827938,0.00003258238,0.0004590258,0.00005154006,0.00002849004,0.000371514,0.0004537321,0.0001004102,0.0004353687,0.00001885794],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920344,0.002154525,0.000692429,0.0002845226,0.0003141612,0.003016229,0.000315294,0.0000379674,0.001150448],"genre_scores_gemma":[0.9933286,0.001063863,0.0009791988,0.00052175,0.0004151412,0.002118823,0.000431991,0.000009539048,0.001131203],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006615631,"threshold_uncertainty_score":0.0221315,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04817295763684427,"score_gpt":0.3298317602822459,"score_spread":0.2816588026454016,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}